Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Soloway

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Urology|June 1, 1997
Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomyM S Cookson, N E Fleshner, S M Soloway, et al.
Urology|October 8, 1998
Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancerN E Fleshner, M S Cookson, S M Soloway, et al.
The Journal of Urology|February 1, 1997
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implicationsM S Cookson, N E Fleshner, S M Soloway, et al.
JAMA|February 6, 1991
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study GroupG W Chodak, N J Vogelzang, R J Caplan, et al.
Anti-Cancer Drugs|October 1, 1990
'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostateR Sharifi, M Soloway, M Clayton, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Urology|March 1, 1997
PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study GroupD G McLeod, C F Johnson, E Klein, et al.
The Journal of Urology|December 1, 1988
Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized studyN M Heney, W W Koontz, B Barton, et al.
The Journal of Urology|November 1, 1992
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasiaH Lepor, S Auerbach, A Puras-Baez, et al.
Progress in Clinical and Biological Research|January 1, 1990
The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU groupT A Splinter, H I Scher, L Denis, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Urology|June 1, 1997
Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomyM S Cookson, N E Fleshner, S M Soloway, et al.
Urology|October 8, 1998
Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancerN E Fleshner, M S Cookson, S M Soloway, et al.
The Journal of Urology|February 1, 1997
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implicationsM S Cookson, N E Fleshner, S M Soloway, et al.
JAMA|February 6, 1991
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study GroupG W Chodak, N J Vogelzang, R J Caplan, et al.
Anti-Cancer Drugs|October 1, 1990
'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostateR Sharifi, M Soloway, M Clayton, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Urology|March 1, 1997
PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study GroupD G McLeod, C F Johnson, E Klein, et al.
The Journal of Urology|December 1, 1988
Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized studyN M Heney, W W Koontz, B Barton, et al.
The Journal of Urology|November 1, 1992
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasiaH Lepor, S Auerbach, A Puras-Baez, et al.
Progress in Clinical and Biological Research|January 1, 1990
The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU groupT A Splinter, H I Scher, L Denis, et al.
Pageof 4